What do you consider a curative radiation dose for a sarcoma?
This is a difficult predicament. We would certainly try to re-resect if at all possible; if not, a consideration could always be made for an amputation, but we try to avoid this if at all possible. Other options during the time of resection are consideration for brachytherapy. We would also discuss systemic therapy and clinical trials. There are some series on the use of regional therapy for extremity sarcomas with limb infusion for recurrent or unresectable sarcomas.
Related to your question, we would consider a radiation boost to the tumor; we usually try to consider a dose of 70Gy with at least 2Gy per fraction, or the BED equivalent.
Join for free or sign in to see the full answer
Unresectable means either extensive or terrible location. Subtotal resection won’t help and will likely contaminate adjacent tissues. Plus the tumor may be displacing OAR. So use as much dose as you can get away with, and reasonably minimize the risk of a disastrous complication. There will be no salvage, so failure to control the tumor will be as bad or worse than a complication. 70 Gy/35 fractions or more. Accelerate if possible. The dose will depend on adjacent OAR.
Join for free or sign in to see the full answer
With gross residual disease that is unresectable, the question is whether there is a curative dose per se. It's reasonable to consider 70 gy. While not in this clinical situation, there is some data on sbrt for oligometastatic sarcoma for gross disease.
Join for free or sign in to see the full answer
Excellent question and I agree with all the above points. SBRT is an excellent choice for smaller lesions, <5 cm.
Targeting 70 Gy is reasonable with modern intensity modulated RT. There are some data to be aware of that can assist in formulating a strategy:
- Harvard series of unresected sarcoma shows a dose response above 63 Gy with increased complications above 68 Gy - Kepka et al., IJROBP 2005
- For spine, there is a phase II study for sarcomas of the with extra-osseous extension, which included a small # of varied non-bone sarcoma histologies
- TRASTS regimen, 30 Gy in 10 fractions plus concurrent Trabectadin, may be useful in the re-irradiation setting
- Note that results of a neoadjuvant cohort of TRASTS, treated with 45 Gy in 25 fractions, ...
Join for free or sign in to see the full answer
Recurrence: I agree with the above. It’s challenging to speak with certainty without details. In general: in this situation we prefer not to radiate gross residual disease. We would likely use chemotherapy to cytoreduce, then reresect or radiate.
Gross residual disease: this situation is exceptionally rare at experienced sarcoma centers. Surgery is generally not performed if gross residual disease is expected (unless palliative).
Join for free or sign in to see the full answer